Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis

Area of Science:

• Cardiology
• Pharmacology
• Critical Care Medicine

Background:

• Vasodilators are typically contraindicated in severe aortic stenosis due to hypotension risks.
• Peripheral vasoconstriction can worsen afterload and myocardial performance in these patients.

Purpose of the Study:

• To evaluate the effects of intravenous nitroprusside on cardiac function in patients with severe aortic stenosis and left ventricular systolic dysfunction.
• To assess the safety and efficacy of nitroprusside as a treatment for decompensated heart failure in this specific patient population.

Main Methods:

• Twenty-five patients with severe aortic stenosis (aortic-valve area ≤1 cm²), depressed ejection fraction (≤0.35), and low cardiac index (≤2.2 L/min/m²) were studied.
• Patients excluded had hypotension (mean arterial pressure <60 mm Hg or requiring vasopressors).
• Intravenous nitroprusside was administered, with doses titrated up to a mean of 128±96 μg/min over 24 hours.

Main Results:

• Nitroprusside significantly increased cardiac index from a baseline of 1.60±0.35 L/min/m² to 2.22±0.44 L/min/m² after 6 hours (P<0.001) and 2.52±0.55 L/min/m² after 24 hours (P<0.001).
• The treatment was well-tolerated with minimal side effects.
• Mean ejection fraction improved from 0.21±0.08 at baseline.

Conclusions:

• Nitroprusside rapidly and substantially improves cardiac function in patients with severe aortic stenosis and decompensated heart failure.
• It serves as a safe and effective bridge therapy for critically ill patients awaiting aortic valve replacement or oral vasodilator treatment.